Novo Nordisk As Stock Probability of Future Stock Price Finishing Over 123.64
NVO Stock | USD 129.21 0.90 0.70% |
Closest to current price Novo long CALL Option Payoff at Expiration
Novo |
Novo Nordisk Target Price Odds to finish over 123.64
The tendency of Novo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current Price | Horizon | Target Price | Odds to stay above $ 123.64 in 90 days |
129.21 | 90 days | 123.64 | about 53.77 |
Based on a normal probability distribution, the odds of Novo Nordisk to stay above $ 123.64 in 90 days from now is about 53.77 (This Novo Nordisk AS probability density function shows the probability of Novo Stock to fall within a particular range of prices over 90 days) . Probability of Novo Nordisk AS price to stay between $ 123.64 and its current price of $129.21 at the end of the 90-day period is about 33.41 .
Considering the 90-day investment horizon Novo Nordisk has a beta of 0.67. This indicates as returns on the market go up, Novo Nordisk average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Novo Nordisk AS will be expected to be much smaller as well. Additionally Novo Nordisk AS has an alpha of 0.2435, implying that it can generate a 0.24 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta). Novo Nordisk Price Density |
Price |
Predictive Modules for Novo Nordisk
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Novo Nordisk AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Novo Nordisk's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Novo Nordisk Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Novo Nordisk is not an exception. The market had few large corrections towards the Novo Nordisk's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Novo Nordisk AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Novo Nordisk within the framework of very fundamental risk indicators.α | Alpha over NYSE Composite | 0.24 | |
β | Beta against NYSE Composite | 0.67 | |
σ | Overall volatility | 6.03 | |
Ir | Information ratio | 0.12 |
Novo Nordisk Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Novo Nordisk for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Novo Nordisk AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.The company has 27.01 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity. | |
On 2nd of April 2024 Novo Nordisk paid $ 0.6638 per share dividend to its current shareholders | |
Latest headline from forbes.com: Wegovy Is Available Again After Shortages, FDA SaysBut Supplies Are Still Limited |
Novo Nordisk Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Novo Stock often depends not only on the future outlook of the current and potential Novo Nordisk's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Novo Nordisk's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 4.5 B | |
Cash And Short Term Investments | 30.2 B |
Novo Nordisk Technical Analysis
Novo Nordisk's future price can be derived by breaking down and analyzing its technical indicators over time. Novo Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Novo Nordisk AS. In general, you should focus on analyzing Novo Stock price patterns and their correlations with different microeconomic environments and drivers.
Novo Nordisk Predictive Forecast Models
Novo Nordisk's time-series forecasting models is one of many Novo Nordisk's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Novo Nordisk's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Novo Nordisk AS
Checking the ongoing alerts about Novo Nordisk for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Novo Nordisk AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
The company has 27.01 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity. | |
On 2nd of April 2024 Novo Nordisk paid $ 0.6638 per share dividend to its current shareholders | |
Latest headline from forbes.com: Wegovy Is Available Again After Shortages, FDA SaysBut Supplies Are Still Limited |
Check out Novo Nordisk Backtesting, Novo Nordisk Valuation, Novo Nordisk Correlation, Novo Nordisk Hype Analysis, Novo Nordisk Volatility, Novo Nordisk History as well as Novo Nordisk Performance. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.631 | Dividend Share 9.4 | Earnings Share 2.67 | Revenue Per Share 51.812 | Quarterly Revenue Growth 0.37 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.